Medical cannabis improved quality of life for inflammatory bowel disease patients in a UK registry
A UK Medical Cannabis Registry case series of 76 IBD patients found significant improvements in disease-specific quality of life, anxiety, sleep, and general health at 1 and 3 months, with mostly mild side effects.
Quick Facts
What This Study Found
Among 76 patients (51 Crohn's, 25 ulcerative colitis), median SIBDQ scores improved at both 1 and 3 months. EQ-5D-5L index values, GAD-7 anxiety scores, and sleep quality also improved significantly at 3 months (all p<0.050). Sixteen patients (21%) reported adverse events, mostly mild to moderate. Prior cannabis consumers showed greater improvement than cannabis-naive individuals.
Key Numbers
76 patients (51 Crohn's, 25 ulcerative colitis); significant improvement in SIBDQ, EQ-5D-5L, GAD-7, and SQS at 3 months (p<0.050); 21.05% adverse events, mostly mild to moderate
How They Did This
Case series from the UK Medical Cannabis Registry analyzing IBD patients prescribed cannabis-based medicinal products. Primary outcomes included changes from baseline in SIBDQ, GAD-7, SQS, and EQ-5D-5L at 1 and 3 months.
Why This Research Matters
While clinical trials have not shown cannabis affects IBD inflammation directly, these real-world data suggest meaningful quality-of-life improvements for patients with refractory symptoms.
The Bigger Picture
The gap between preclinical promise and clinical trial results for cannabis in IBD may partly reflect outcome measurement. Quality-of-life improvements matter to patients even without measurable changes in inflammation markers.
What This Study Doesn't Tell Us
Uncontrolled case series with no placebo group. Small sample size. Short follow-up period. Registry data may reflect selection bias toward motivated patients. No objective inflammation biomarkers assessed.
Questions This Raises
- ?Would these quality-of-life improvements persist long-term?
- ?Is the greater response in prior cannabis users due to familiarity with effects or self-selection of responders?
Trust & Context
- Key Stat:
- Significant quality-of-life improvements at 3 months with 21% mild adverse event rate
- Evidence Grade:
- Real-world registry data showing consistent improvements across multiple outcomes, but uncontrolled design without placebo comparison limits conclusions.
- Study Age:
- Published 2023
- Original Title:
- The effect of medical cannabis in inflammatory bowel disease: analysis from the UK Medical Cannabis Registry.
- Published In:
- Expert review of gastroenterology & hepatology, 17(1), 85-98 (2023)
- Authors:
- Dalavaye, Nishaanth, Erridge, Simon(22), Nicholas, Martha, Pillai, Manaswini, Bapir, Lara, Holvey, Carl, Coomber, Ross, Rucker, James J, Hoare, Jonathan, Sodergren, Mikael H
- Database ID:
- RTHC-04481
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
Does medical cannabis help with inflammatory bowel disease?
In this UK registry study of 76 patients, cannabis-based products improved IBD-specific quality of life, anxiety, sleep, and general health at 3 months, though no objective inflammation measures were assessed.
What side effects did IBD patients experience from medical cannabis?
About 21% reported adverse events, but the majority were classified as mild to moderate in severity. No serious adverse events were highlighted.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04481APA
Dalavaye, Nishaanth; Erridge, Simon; Nicholas, Martha; Pillai, Manaswini; Bapir, Lara; Holvey, Carl; Coomber, Ross; Rucker, James J; Hoare, Jonathan; Sodergren, Mikael H. (2023). The effect of medical cannabis in inflammatory bowel disease: analysis from the UK Medical Cannabis Registry.. Expert review of gastroenterology & hepatology, 17(1), 85-98. https://doi.org/10.1080/17474124.2022.2161046
MLA
Dalavaye, Nishaanth, et al. "The effect of medical cannabis in inflammatory bowel disease: analysis from the UK Medical Cannabis Registry.." Expert review of gastroenterology & hepatology, 2023. https://doi.org/10.1080/17474124.2022.2161046
RethinkTHC
RethinkTHC Research Database. "The effect of medical cannabis in inflammatory bowel disease..." RTHC-04481. Retrieved from https://rethinkthc.com/research/dalavaye-2023-the-effect-of-medical
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.